Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
SAN MATEO, CA, June 23, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock...
—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a...
--Chief Medical Officer Dr. Barbara Klencke, to be joined by leading myelofibrosis experts Drs. Aaron Gerds, Stephen Oh and Srdan Verstovsek-- SAN MATEO, Calif., June 14, 2021 /CNW/ - Sierra...
—Additional poster presentation highlights improved transfusion independence of momelotinib irrespective of baseline degree of anemia, platelet count or transfusion status— SAN MATEO, Calif., June...
—Georgia Erbez and Christy Oliger bring additional strategy, finance and commercial experience as Sierra prepares for commercialization of momelotinib— SAN MATEO, Calif., June 3, 2021 /CNW/ - Sierra...
SAN MATEO, Calif., May 25, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced...
SAN MATEO, Calif., May 21, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock...
—New momelotinib analysis examining the association between transfusion independence and overall survival to be presented— SAN MATEO, Calif., May 19, 2021 May 19, 2021 - Sierra Oncology, Inc. (SRRA), ...
– Oral presentation for new momelotinib analysis examines association between transfusion independence and overall survival – – Poster presentation to highlight improved transfusion independence of...
– Pivotal MOMENTUM Phase 3 Trial Anticipated to Complete Enrollment in June 2021 – – Topline Data Now Expected in Q1 2022 – SAN MATEO, Calif., May 7, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a...
SAN MATEO, Calif., March 23, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a...
– MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 – – Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in...
—HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15th— —Oppenheimer Healthcare Conference at 1:50 pm ET on March 17th— SAN MATEO, ...
SAN MATEO, Calif., Feb. 12, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced ...
SAN MATEO, Calif., Feb. 9, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock...
VANCOUVER, BC, Jan. 5, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that ...
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /CNW/ - Sierra Oncology, Inc....
--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage ...
--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan Verstovsek-- VANCOUVER, BC, Dec. 1, 2020 /CNW/ - Sierra...
VANCOUVER, BC, Nov. 25, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of...
VANCOUVER, BC, Nov. 12, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of...
- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage...
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company...
VANCOUVER, BC, Oct. 2, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1...
VANCOUVER, BC, Sept. 14, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.